Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills

Objective: To investigate the effect of Compound Danshen Dripping Pills （CDDP）on improving coronary flow reserve（CFR） in patients with coronary microvascular disease (CMVD) and to evaluate their efficacy and safety. Study Design: Randomized, double-blind, placebo-controlled, multicenter clinical trial. Study population: Patients with ischemia-related CMVD and myocardial infarction-related CMVD. Intervention：Treatment group：standard therapy plus CDDP, Twenty pills (27 mg each) orally, three times daily after meals.Control group：standard therapy plus matching placebo, Twenty pills (27 mg each) orally, three times daily after meals.Treatment duration 12 months. Primary Endpoint: Change in CFRmax from baseline to Month 12 (ΔCFRmax-12m) by Transthoracic Doppler echocardiography(TTE).